Biomimetic Nanoplatform for Fibrosis Remodeling and Anti-PD-1 Potentiation via Cu+/Ca2+ Ion Dysregulation and TGF-β Inhibition in PDAC. (PubMed, Adv Sci (Weinh)) - Oct 25, 2026 - "RPm@CC-LY achieves efficient tumor accumulation and effectively attenuates fibrosis through sustained release of Transforming growth factor-β (TGF-β) inhibitor LY2157299 (LY)...Notably, when combined with anti-PD-1 (αPD1) therapy, RPm@CC-LY induces a systemic immune response in mice. This work establishes a synergistic nanotherapeutic strategy that integrates fibrosis remodeling with ion interference therapy to overcome the immunotherapeutic barriers posed by fibrosis in PDAC."
Journal • Fibrosis • Immunology • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • TGFB1
|
|
Feng Xiong; Jianmei Li; Jie Dai; Li Yang; Qinlong Wen; Xingchen Peng; Zhigong Wei
|